

IPR and Innovation

1. [Delhi HC resumes trial in Glenmark-Merck Sharp and Dohme patent case](#) – Mint
2. [Hyderabad-based Lee Pharma files CL application for AstraZeneca's diabetes drug](#) – Business Standard
3. [Innovation is India's key growth driver, says Narendra Modi](#) – Mint
4. [TS govt propounds innovate, incubate and incorporate, as new mantra to build next gen healthcare tech](#) – Pharmabiz.com
5. [Patent to CSIR's iodising agent](#) – Business Standard

Access to Healthcare

1. [Govt to set up ADR centres in corporate hospitals to strengthen PvPI](#) – Pharmabiz.com
2. [Parliamentary panel asks govt to provide insurance cover to all HIV positive patients](#) – Pharmabiz.com
3. [Free Drug Scheme at CHCs by August-end](#) – Indian Express
4. [Pharma Infra Taking It To The Next Level](#) – The Financial Express
5. [Why pharmaceutical firms in India hardly took the village road](#) – The Economic Times
6. [Health department ambulances too could go the 108 way](#) – The Times of India
7. [Gujarat to adopt Tamil Nadu, Maharashtra models to improve HDI](#) – The Times of India

Medical & Regulatory

1. [Provisions of DPCO, 2013 applicable to notified medical devices: NPPA](#) – Pharmabiz.com
2. [TS Biodiversity Board to make MNCs accountable](#) – The Hindu
3. [Govt forms panel to check UNICEF's child survey report](#) – The Statesman

Others

1. [Over 100 cos exhibited products at 'Pharmac South' in Chennai](#) – Pharmabiz

IPR and Innovation

1. [Delhi HC resumes trial in Glenmark-Merck Sharp and Dohme patent case](#) - Mint
The dispute is regarding the manufacturing of sitagliptin, a key active molecule in Glenmark's anti-diabetes drug
New Delhi: The Delhi high court on Monday began hearing arguments in a patent dispute between Glenmark Pharmaceuticals Ltd and US-based Merck Sharp and Dohme, a unit of Merck and Co. Inc. The dispute is regarding the manufacturing of sitagliptin, a key active molecule in Glenmark's anti-diabetes drug. Merck Sharp and Dohme in 2013 moved the high court against Glenmark, alleging patent infringement. Judge Rajiv Sahai Endlaw refused to grant an injunction against Glenmark, but a two-judge bench of the high court later reversed this position, finding merit in Merck's plea.
2. [Hyderabad-based Lee Pharma files CL application for AstraZeneca's diabetes drug](#) – Business Standard
The move could be taken as a positive sign in the evolution of compulsory licensing in India, said the company

Hyderabad-based Lee Pharma, which has filed a [Compulsory Licence \(CL\)](#) application on drug major AstraZeneca's patented diabetes medicine [Saxagliptin](#) last month, has said that at present this is the most efficient drug that can substitute the painful insulin injectables for the diabetes patients in India, which has attracted the company to look for manufacturing and marketing it. The multi national company is not able to meet the demand in the market, said company sources.

3. [Innovation is India's key growth driver, says Narendra Modi](#) – Mint
New Delhi: Prime Minister Narendra Modi on Sunday said he wants India to emerge as the innovation hub where the next big idea is driven by the power of technology. Replying to questions posted by netizens under the digital dialogue initiative, he said the “world is changing, quicker than ever before” and “we cannot remain oblivious to that. If we don't innovate, if we don't come up with cutting edge products, there will be stagnation”. He told entrepreneurs and start-ups to keep innovating. “Start-ups are the engines of exponential growth, manifesting the power of innovation. Thus, my message—keep innovating. Innovation is what will help us grow faster,” he said.
4. [TS govt propounds innovate, incubate and incorporate, as new mantra to build next gen healthcare tech](#) – Pharmabiz.com
The Telangana state government has propounded new mantra of innovate, incubate and incorporate to build next generation healthcare technology. Taking part in 'ReDx--Engineering the Eye' workshop hosted by L V Prasad Eye Institute in Hyderabad, K.T. Rama Rao, minister for information technology, government of Telangana said “The technology in eye care is in a primitive stage and is a great opportunity for budding innovators to bring out innovations. As Hyderabad is the IT and healthcare capital, therefore it is necessary to integrate both and develop some innovations for healthcare.
5. [Patent to CSIR's iodising agent](#) – Business Standard
The Intellectual Property Appellate Board (IPAB) has directed the Patent Office to grant a patent to the national R&D organisation Council of Scientific & Industrial Research (CSIR) for a novel iodising agent finding its use in iodised salt. The Patent Office, New Delhi, had earlier refused to provide its nod on a pre-grant opposition filed by Hindustan Lever. The patent application, titled 'iodising agent and process for preparation thereof', related to a novel process for the preparation of stable iodising agent, which can be effectively used in the formulation of iodised salt, wherein it offers stability to iodine. The CSIR had filed the application on June 30, 2004, which was published on June 23, 2006.

Access to Healthcare

1. [Govt to set up ADR centres in corporate hospitals to strengthen PvPI](#) – Pharmabiz.com
Union health ministry is in the process of setting up Adverse Drug Reaction Monitoring Centres (AMCs) in teaching hospitals and centres covered under the National Health Programmes (NHP). Corporate hospitals will also be roped in as a part of the programme, an official informed. Ghaziabad based Indian Pharmacopoeia Commission (IPC) which is the national coordination centre (NCC) for Pharmacovigilance Programme of India (PvPI) will serve as a nodal agency for the AMCs. Currently, 150 AMCs have been established in India under PvPI.
2. [Parliamentary panel asks govt to provide insurance cover to all HIV positive patients](#) – Pharmabiz.com
The Department-Related Parliamentary Standing Committee on Health and Family Welfare has recommended to the government to provide both life and health insurance cover to all HIV positive people without any discrimination preferably at normal rate of premium. The Committee headed by Satish Chandra Misra, had recently submitted its report to both Houses of Parliament. In its 85th report, the Committee had given its green signal for the controversial Human Immunodeficiency Virus and Acquired Immune Deficiency Syndrome (Prevention and Control) Bill, 2014 and has recommended to the government to pass the Bill without further delay.
3. [Free Drug Scheme at CHCs by August-end](#) – Indian Express
BHUBANESWAR: The free drug distribution scheme Niramaya will be expanded to all community health centres (CHCs) by the end of August, Health Minister Atanu Sabyasachi Nayak said here on Monday. The

scheme, launched in May this year, has been operationalised in three medical college and hospitals, Acharya Harihar Regional Cancer Centre (AHRCC), Sardar Vallabhbhai Patel Post Graduate Institute of Paediatrics, Cuttack along with all 32 district headquarters hospitals and 27 sub-divisional hospitals by June-end. The scheme would be rolled out in 377 CHCs and 84 other hospitals and health facilities run by the Government in these two months. In June, 4.50 lakh patients benefited from the scheme across hospitals where Niramaya is in operation.

4. [Pharma Infra Taking It To The Next Level](#) – The Financial Express
Pharma exports grew at just 1.2 per cent in FY 2014. Can the latest [Foreign Trade Policy](#) galvanise creation of better infrastructure to boost the growth rate? By Usha Sharma
The [Narendra Modi](#)-led NDA government is aggressively working to enhance infrastructure across the country. As part of this mission, the government is building up a system to improve connectivity between remote areas to developed cities and metros for better engagement. To accomplish this, the Department of Commerce, Ministry of Commerce and Industry had included provisions in the recently released Foreign Trade Policy (FTP) 2015-2020, aimed at helping companies set up manufacturing facilities in Jammu and Kashmir, and the Northeastern states.
5. [Why pharmaceutical firms in India hardly took the village road](#) – The Economic Times
MUMBAI: It's easier to spot an auto showroom in a small town than to locate a pharmacy that sells anything beyond cough and cold, and birth-control pills. If you are desperate to get hold of life-saving drugs, or insulin or drug for epileptic seizure, chances are you would run out of luck. That's because pharma firms have largely stayed away from villages. At a time when every business - from toothpaste to mobile handsets to luxury cars - are luring customers in rural India, this may appear strange. But there are reasons. The growth of the Rs 85,000-crore pharma industry in India has been largely driven by demand from urban Indian patients. The penetration of pharma companies in villages (with population less than 10,000) is limited: their presence is largely restricted to selling acute therapy products -- medicines for common or short-term ailments.
6. [Health department ambulances too could go the 108 way](#) – The Times of India
MANGALURU: Ambulances under the department of health and family welfare could well go the way if a hint given by minister for health and family welfare U T Khader is anything to go by. At present, the state government offers 108 ambulance service to the needy under the Arogya Kavach scheme with GVK Foundation running it on behalf of the state government under a MoU. Now the department intends to give a similar facelift to its ambulances as well.
7. [Gujarat to adopt Tamil Nadu, Maharashtra models to improve HDI](#) – The Times of India
GANDHINAGAR: To improve Gujarat's performance on the Human Development Index (HDI) count, the state government has decided to adopt the successful public health model of Tamil Nadu, Maharashtra and some best practices from Karnataka. At the recent three-day Chintan Shibir, a detailed presentation was made on the Tamil Nadu and Maharashtra public health models. The state government decided to adopt best practices in these states to improve HDI of state which has remained poor due to poor health services to the people.

Medical & Regulatory

1. [Provisions of DPCO, 2013 applicable to notified medical devices: NPPA](#) – Pharmabiz.com
The National Pharmaceutical Pricing Authority (NPPA) has clarified that orthopaedic implants along with other medical devices will be treated as drugs, hence provisions of DPCO, 2013 are applicable to notified medical devices. Refuting the contention of the medical devices manufacturers, especially the manufacturers of orthopaedic implants, that the provisions of DPCO 2013 are not applicable to medical devices, the NPPA said, "Para 20 of DPCO, 2013 provides for monitoring of non-scheduled formulations. Orthopaedic implants along with other medical devices are notified as 'drug' under Drugs & Cosmetics Act & Rules thereunder. Therefore your contention that the provisions of DPCO, 2013 are not applicable to medical devices is totally incorrect."

2. [TS Biodiversity Board to make MNCs accountable](#) – The Hindu

The Telangana State Biodiversity Board is likely to hold a dialogue with seed and pharma MNCs towards making them accountable to the National Biodiversity Authority when exporting the indigenous bio-resources. The Board has recently identified names of 10 prominent companies from the genetic material kept for export at the quarantine facility of the GMR International Airport at Shamshabad. All the companies have offices in Hyderabad. The companies, all multinationals, have been refuting any accountability to the Board for quite some time, even while exporting the seed and plant germplasm in a big way, officials from the Board informed. Hyderabad being the hub of seed and pharma/biotech companies, efforts are on by the Board to pin them down into paying up prescribed fee.

3. [Govt forms panel to check UNICEF's child survey report](#) – The Statesman

Under fire for holding back state- wise findings of UNICEF's Rapid Survey on Children, the Women and Child Development Ministry has constituted a committee to examine the report following differences of opinion over the survey methodology. The committee, which is likely to submit its report within a week, includes officials from the ministries of Health and Family Welfare, and Statistics and Programme Implementation. It will work upon to reach a consensus on the contentious UNICEF report, which has indicated a reduction in the immunisation cover of children.

"We held a meeting with the ministries of Health and Statistics and decided to form a committee as there was difference of opinion on the state-level findings of the UNICEF survey. It is likely to submit its report within a week," a senior Women and Child Development Ministry official told PTI.

Others

1. [Over 100 cos exhibited products at 'Pharmac South' in Chennai](#) - Pharmabiz

Over one hundred companies in the pharma SME sector in the southern states showcased a huge lineup of products at the trade exhibition 'Pharmac South 2015', organised in Chennai on July 3rd and 4th. Positive responses were received from over 2000 business buyers who have visited the site for the two-day event. The pharmaceutical and nutraceutical companies participated in the trade show have used the platform mostly to educate their potential customers about the production facilities at their plants, the QA and QC systems, technology prowess and their product portfolios. The exhibition, in fact, showed the strength of the south Indian pharmaceutical companies for manufacturing and marketing of quality pharmaceutical, nutraceutical and Ayush products.